期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HPLC法测定厄洛替尼片的含量 被引量：5

Content Determination of Erlotinib Tablets by HPLC
原文传递
导出
摘要 目的:建立测定厄洛替尼片含量的方法。方法:采用高效液相色谱法。色谱柱为PhenomexexLuna-C18,流动相为甲醇-pH3.5磷酸盐缓冲液(25:75,V/V),流速为1.0ml/min,检测波长为342nm,柱温为30℃。结果:厄洛替尼检测质量浓度线性范围为10～100μg/m(lr=0.9999),平均加样回收率为100.36%,RSD=0.62%(n=6)。结论:本方法操作简便、结果准确,可用于该制剂中厄洛替尼的含量测定。 OBJECTIVE： To establish a method for the content determination of Erlotinib tablets. METHODS： HPLC method was adopted. The determination was performed on Phenomexex Luna-Cl, column with mobile phase consisted of methanol-pH 3.5 phosphate buffer solution （25 ： 75, V/V） at the flow rate of 1.0 ml/min. The detection wavelength was set at 342 nm, and the col- umn temperature was 30 ℃. RESULTS： The linear rang of erlotinib was 10-100 μg/ml （r=0.999 9） with an average recovery of 100.36% and RSD= 0.62% （n=6）, CONCLUSIONS： The established method is simple and accurate. It can be applied for content determination of erlotinib in Erlotinib tablets.
作者 胡剑锋
机构地区 江苏省盛泽医院
出处 《中国药房》 CAS CSCD 2013年第5期458-459,共2页 China Pharmacy
关键词 厄洛替尼片 高效液相色谱法 含量测定 Erlotinib tablets HPLC Content determination
分类号 R927.2 [医药卫生—药学] R979.1 [医药卫生—药品]
  • 相关文献

参考文献3

  • 1黄逸生,周志凌,雷丽婵,赵建华,黄楚权,邓海媚,吴一龙.高效液相色谱质谱串联法检测厄洛替尼血浆浓度[J].中南药学,2011,9(11):801-804. 被引量：4
  • 2Bouchet S, Chauzit E, Ducint D, et al. Simultaneous de- termination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS [J]. Clin ChimActa,2011,412(11/12) : 1 060.
  • 3Chahbouni A, den Burger JC, Vos RM, et al. Simultane- ous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry[J]. Ther Drug Monit, 2009,31(6) : 683.

二级参考文献18

  • 1NCCN Non-small Cell Lung Cancer Practice Guideline [M]. Practice Guideline in Oncology (v2), 2009: 20-21.
  • 2Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor [J]. J Clin Oncol, 2004, 22 (15): 3080-3090.
  • 3Bouchet S, Chauzit E, Ducint D, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS [J]. Clin Chim Acta, 2011, 412 (12): 11-12.
  • 4Chahbouni A, den Burger JC, Vos RM, et al. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry [J]. Ther Drug Monit, 2009, 12 (6): 683-687.
  • 5Roche S, McMahon G, Clynes M, et al. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib [J]. Chromatogr B Analyt Technol Biomed Life Sci, 2009, 877 (31): 3982- 3990.
  • 6Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non- small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR. 21 [J]. Clin Lung Cancer, 2006, 7 (6): 389-394.
  • 7Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome [J]. N Engl J Med, 2005, 353 (2):133-144.
  • 8Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [J]. N Engl J Med, 2005, 353 (2): 123-132.
  • 9Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. [J]. Cancer, 2001, 92 (6): 1525-1530.
  • 10Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlo tinib [J]. Proc Natl Aead Sci USA, 2004, 101 (36):13306-13311.

共引文献3

同被引文献35

引证文献5

二级引证文献17

中国药房
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部